Please login to the form below

Not currently logged in
Email:
Password:

Boehringer - Lilly file empagliflozin for European approval

EMA begins review of the companies' new type 2 diabetes drug

Empaglifozin moleculeThe European Medicines Agency (EMA) has begun its review of Boehringer Ingelheim and Lilly's new oral type 2 diabetes drug empagliflozin.

The treatment is a sodium glucose co-transporter-2 (SGLT-2) inhibitor, the same new class of type 2 diabetes treatment as Bristol-Myers Squibb and AstraZeneca's Foxiga and Johnson & Johnson's canaglifozin.

SGLT-2 inhibitors work independently of insulin and appear to provide sustained improvements in blood glucose, whilst also alleviating the weight gain seen with other oral anti-diabetic agents (OADs).

“We are pleased the EMA has accepted our marketing authorisation application for a potential new treatment option to help patients better manage their type 2 diabetes mellitus,” said Prof Klaus Dugi, corporate senior vice president medicine, Boehringer Ingelheim.

The European filing follows empagliflozin's recent submission to US regulators for approval, giving it a chance to catch up with its rival SGLT-2 inhibitors.

Bristol-Myers Squibb and AstraZeneca's Forxiga (dapagliflozin) has already been approved in the EU, but delayed in the US, while Johnson & Johnson's canagliflozin has been filed for approval in the US and Europe.

Empagliflozin is one of the four compounds covered by Boehringer and Lilly's 2011 co-development agreement.

Early this year Lilly took back sole development and marketing rights to LY2605541 - a basal insulin product, but the partners are still working together on Tadjenta (linagliptin) and LY2963016, a second basal insulin analogue.

28th March 2013

From: Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
mXm Medical Communications

mXm Medical Communications meets the needs of pharmaceutical marketers and medics who require a highly experienced, bespoke service from their...

Latest intelligence

eyeforpharma_h_logo.png
Make Anthill your strategic partner in Barcelona
We are excited to attend and exhibit at eyeforpharma Barcelona 2017 (March 14-16th), and present two multichannel strategy workshops....
Why we need to bring empathy back into medcomms
Medical communications requires you to bring more empathy to your communications...
2016: The year when deal-makers took stock?
Merger-mania and asset swaps slowed and joint ventures were back in fashion...

Infographics